who qualifies for glp 1 medications Holding GLP-1 Agonists Prior to Elective Procedures Patient education tips for GLP-1,

35 business days, excluding weekends and holidays

Reported protocols from research settings and case literature include: Subcutaneous self-injection at doses of 0.5-1 mg Loading phase protocols followed by maintenance dosing Typical research doses of 0.025 mg/kg in clinical studies No standardized reconstitution or storage protocols in unregulated use The self-administration model and lack of pharmaceutical-grade products create additional safety risks absent from the Melanotan-1 paradigm

Corcoran, C., & Jacobs, T

These patches do not contain semaglutide, tirzepatide, or other GLP-1 drugs, and theres no clinical evidence they produce comparable appetite or weight loss effects